The role of thyroid hormone signaling in the prevention of digestive system cancers

International Journal of Molecular Sciences

Volumn 14, Issue 8, 2013, Pages 16240-16257

  Brown, Adam R ^a,b   Simmen, Rosalia C M ^a,b   Simmen, Frank A ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Colorectal cancer; Esophageal cancer; Gastric cancer; Liver cancer; Pancreatic cancer; Thyroid hormone; Thyroid hormone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; DEBUTYLDRONEDARONE; HORMONE ANTAGONIST; IODIDE PEROXIDASE; ISOPROTEIN; LIOTHYRONINE; MESSENGER RNA; PLACEBO; SELENIUM; THYROID HORMONE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME INACTIVATION; ESOPHAGUS CANCER; HETEROZYGOSITY; HOMEOSTASIS; HORMONE ACTION; HORMONE RESPONSE; HUMAN; HYPOTHYROIDISM; LIVER CELL CARCINOMA; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STOMACH CANCER; THRB GENE; THYROID DISEASE; THYROID HORMONE SYNTHESIS; TRALPHA GENE; TRBETA GENE; TUMOR INVASION;

DIGESTIVE SYSTEM NEOPLASMS; HUMANS; INTEGRIN ALPHAVBETA3; IODIDE PEROXIDASE; LIVER; PROTEIN ISOFORMS; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID HORMONES;

EID: 84886905254     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140816240     Document Type: Review

References (122)

1. Dietrich, J.W.; Landgrafe, G.; Fotiadou, E.H. TSH and thyrotropic agonists: Key actors in thyroid homeostasis. J. Thyroid Res. 2012, 2012, 351864:1-351864:29.
2. Bianco, A.C.; Salvatore, D.; Gereben, B.; Berry, M.J.; Larsen, P.R. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 2002, 23, 38-89.
3. Bianco, A.C.; Kim, B.W. Deiodinases: Implications of the local control of thyroid hormone action. J. Clin. Investig. 2006, 116, 2571-2579.
4. Bates, J.M.; St Germain, D.L.; Galton, V.A. Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat. Endocrinology 1999, 140, 844-851.
5. Brent, G.A. The molecular basis of thyroid hormone action. N. Engl. J. Med. 1994, 331, 847-853.
6. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83, 835-839.
7. Yen, P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81, 1097-1142.
8. Klug, A.; Schwabe, J.W. Protein motifs 5. Zinc fingers. FASEB J. 1995, 9, 597-604.
9. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
10. Umesono, K.; Murakami, K.K.; Thompson, C.C.; Evans, R.M. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 1991, 65, 1255-1266.
11. Lazar, M.A. Thyroid hormone action: A binding contract. J. Clin. Investig. 2003, 112, 497-499.
12. Sap, J.; Munoz, A.; Damm, K.; Goldberg, Y.; Ghysdael, J.; Leutz, A.; Beug, H.; Vennstrom, B. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986, 324, 635-640.
13. Weinberger, C.; Thompson, C.C.; Ong, E.S.; Lebo, R.; Gruol, D.J.; Evans, R.M. The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986, 324, 641-646.
14. Cheng, S.Y. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev. Endocr. Metab. Disord. 2000, 1, 9-18.
15. Kliewer, S.A.; Umesono, K.; Mangelsdorf, D.J.; Evans, R.M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992, 355, 446-449.
16. Bergh, J.J.; Lin, H.Y.; Lansing, L.; Mohamed, S.N.; Davis, F.B.; Mousa, S.; Davis, P.J. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146, 2864-2871.
17. Lin, H.Y.; Sun, M.; Tang, H.Y.; Lin, C.; Luidens, M.K.; Mousa, S.A.; Incerpi, S.; Drusano, G.L.; Davis, F.B.; Davis, P.J. L-Thyroxine vs. 3,5,33′-triiodo-L-thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am. J. Physiol. Cell Physiol. 2009, 296, C980-C991.
18. Lin, H.Y.; Tang, H.Y.; Shih, A.; Keating, T.; Cao, G.; Davis, P.J.; Davis, F.B. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007, 72, 180-187.
19. Tang, H.Y.; Lin, H.Y.; Zhang, S.; Davis, F.B.; Davis, P.J. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004, 145, 3265-3272.
20. Davis, F.B.; Mousa, S.A.; O'Connor, L.; Mohamed, S.; Lin, H.Y.; Cao, H.J.; Davis, P.J. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ. Res. 2004, 94, 1500-1506.
21. Yalcin, M.; Dyskin, E.; Lansing, L.; Bharali, D.J.; Mousa, S.S.; Bridoux, A.; Hercbergs, A.H.; Lin, H.Y.; Davis, F.B.; Glinsky, G.V.; et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 2010, 95, 1972-1980.
22. Yalcin, M.; Lin, H.Y.; Sudha, T.; Bharali, D.J.; Meng, R.; Tang, H.Y.; Davis, F.B.; Stain, S.C.; Davis, P.J.; Mousa, S.A. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm. Cancer 2013, 4, 176-185.
23. Yalcin, M.; Bharali, D.J.; Lansing, L.; Dyskin, E.; Mousa, S.S.; Hercbergs, A.; Davis, F.B.; Davis, P.J.; Mousa, S.A. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 2009, 29, 3825-3831.
24. Yalcin, M.; Bharali, D.J.; Dyskin, E.; Dier, E.; Lansing, L.; Mousa, S.S.; Davis, F.B.; Davis, P.J.; Mousa, S.A. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 2010, 20, 281-286.
25. Kress, E.; Samarut, J.; Plateroti, M. Thyroid hormones and the control of cell proliferation or cell differentiation: Paradox or duality? Mol. Cell. Endocrinol. 2009, 313, 36-49.
26. Das, B.; Cai, L.; Carter, M.G.; Piao, Y.L.; Sharov, A.A.; Ko, M.S.; Brown, D.D. Gene expression changes at metamorphosis induced by thyroid hormone in Xenopus laevis tadpoles. Dev. Biol. 2006, 291, 342-355.
27. Heimeier, R.A.; Das, B.; Buchholz, D.R.; Fiorentino, M.; Shi, Y.B. Studies on Xenopus laevis intestine reveal biological pathways underlying vertebrate gut adaptation from embryo to adult. Genome Biol. 2010, 11, R55.
28. Shi, Y.B.; Brown, D.D. The earliest changes in gene expression in tadpole intestine induced by thyroid hormone. J. Biol. Chem. 1993, 268, 20312-20317.
29. Shi, Y.B.; Wong, J.; Puzianowska-Kuznicka, M.; Stolow, M.A. Tadpole competence and tissue-specific temporal regulation of amphibian metamorphosis: Roles of thyroid hormone and its receptors. Bioessays 1996, 18, 391-399.
30. Galton, V.A. The roles of the iodothyronine deiodinases in mammalian development. Thyroid 2005, 15, 823-834.
31. Buchholz, D.R.; Paul, B.D.; Fu, L.; Shi, Y.B. Molecular and developmental analyses of thyroid hormone receptor function in Xenopus laevis, the African clawed frog. Gen. Comp. Endocrinol. 2006, 145, 1-19.
32. Menard, D. Functional development of the human gastrointestinal tract: Hormone-and growth factor-mediated regulatory mechanisms. Can. J. Gastroenterol. 2004, 18, 39-44.
33. Plateroti, M.; Chassande, O.; Fraichard, A.; Gauthier, K.; Freund, J.N.; Samarut, J.; Kedinger, M. Involvement of T3Ralpha-and beta-receptor subtypes in mediation of T3 functions during postnatal murine intestinal development. Gastroenterology 1999, 116, 1367-1378.
34. Jumarie, C.; Malo, C. Alkaline phosphatase and peptidase activities in Caco-2 cells: Differential response to triiodothyronine. In Vitro Cell. Dev. Biol. Anim. 1994, 30, 753-760.
35. Matosin-Matekalo, M.; Mesonero, J.E.; Laroche, T.J.; Lacasa, M.; Brot-Laroche, E. Glucose and thyroid hormone co-regulate the expression of the intestinal fructose transporter GLUT5. Biochem. J. 1999, 339, 233-239.
36. Kress, E.; Rezza, A.; Nadjar, J.; Samarut, J.; Plateroti, M. The thyroid hormone receptor-alpha (TRalpha) gene encoding TRalpha1 controls deoxyribonucleic acid damage-induced tissue repair. Mol. Endocrinol. 2008, 22, 47-55.
37. Ishizuya-Oka, A.; Hasebe, T.; Buchholz, D.R.; Kajita, M.; Fu, L.; Shi, Y.B. Origin of the adult intestinal stem cells induced by thyroid hormone in Xenopus laevis. FASEB J. 2009, 23, 2568-2575.
38. Sirakov, M.; Plateroti, M. The thyroid hormones and their nuclear receptors in the gut: From developmental biology to cancer. Biochim. Biophys. Acta 2011, 1812, 938-946.
39. Sun, G.; Hasebe, T.; Fujimoto, K.; Lu, R.; Fu, L.; Matsuda, H.; Kajita, M.; Ishizuya-Oka, A.; Shi, Y.B. Spatio-temporal expression profile of stem cell-associated gene LGR5 in the intestine during thyroid hormone-dependent metamorphosis in Xenopus laevis. PLoS One 2010, 5, e13605.
40. Turkyilmaz, A.; Eroglu, A.; Aydin, Y.; Yilmaz, O.; Karaoglanoglu, N. A new risk factor in oesophageal cancer aetiology: Hyperthyroidism. Acta Chir. Belg. 2010, 110, 533-536.
41. Li, H.; Xu, X.C. Lost expression of thyroid hormone receptor-alpha1 mRNA in esophageal cancer. Front. Biol. 2012, 7, 368-373.
42. Qiu, H.; Lotan, R.; Lippman, S.M.; Xu, X.C. Lack of correlation between expression of retinoic acid receptor-beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer. Genes Chromosomes Cancer 2000, 28, 196-202.
43. Zhang, W.; Rashid, A.; Wu, H.; Xu, X.C. Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues. J. Cancer Res. Clin. Oncol. 2001, 127, 237-242.
44. Behne, D.; Kyriakopoulos, A.; Gessner, H.; Walzog, B.; Meinhold, H. Type I iodothyronine deiodinase activity after high selenium intake, and relations between selenium and iodine metabolism in rats. J. Nutr. 1992, 122, 1542-1546.
45. Li, J.Y.; Taylor, P.R.; Li, B.; Dawsey, S.; Wang, G.Q.; Ershow, A.G.; Guo, W.; Liu, S.F.; Yang, C.S.; Shen, Q. Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J. Natl. Cancer Inst. 1993, 85, 1492-1498.
46. Wang, C.S.; Lin, K.H.; Hsu, Y.C. Alterations of thyroid hormone receptor alpha gene: Frequency and association with Nm23 protein expression and metastasis in gastric cancer. Cancer Lett. 2002, 175, 121-127.
47. Kandemir, E.G.; Yonem, A.; Narin, Y. Gastric carcinoma and thyroid status. J. Int. Med. Res. 2005, 33, 222-227.
48. Syrigos, K.N.; Konstantoulakis, M.M.; Constantoulakis, M.; Marafelia, P.; Koutras, D.; Golematis, B.C. Thyroid autoantibodies and thyroid function in patients with gastric cancer. Acta Oncol. 1994, 33, 905-907.
49. Centanni, M.; Marignani, M.; Gargano, L.; Corleto, V.D.; Casini, A.; Delle, F.G.; Andreoli, M.; Annibale, B. Atrophic body gastritis in patients with autoimmune thyroid disease: An underdiagnosed association. Arch. Intern. Med. 1999, 159, 1726-1730.
50. Kato, I.; Tominaga, S.; Ito, Y.; Kobayashi, S.; Yoshii, Y.; Matsuura, A.; Kameya, A.; Kano, T. Atrophic gastritis and stomach cancer risk: Cross-sectional analyses. Jpn. J. Cancer Res. 1992, 83, 1041-1046.
51. Wang, J.; Griggs, N.D.; Tung, K.S.; Klein, J.R. Dynamic regulation of gastric autoimmunity by thyroid hormone. Int. Immunol. 1998, 10, 231-236.
52. Blot, W.J.; Li, J.Y.; Taylor, P.R.; Guo, W.; Dawsey, S.; Wang, G.Q.; Yang, C.S.; Zheng, S.F.; Gail, M.; Li, G.Y. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 1993, 85, 1483-1492.
53. Iishi, H.; Tatsuta, M.; Baba, M.; Yamamoto, R.; Taniguchi, H. Enhancement by thyroxine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Br. J. Cancer 1993, 68, 515-518.
54. Grijota-Martinez, C.; Samarut, E.; Scanlan, T.S.; Morte, B.; Bernal, J. In vivo activity of the thyroid hormone receptor beta-and alpha-selective agonists GC-24 and CO23 on rat liver, heart, and brain. Endocrinology 2011, 152, 1136-1142.
55. Ocasio, C.A.; Scanlan, T.S. Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist. ACS Chem. Biol. 2006, 1, 585-593.
56. Spencer, J.G. The influence of the thyroid in malignant disease. Br. J. Cancer 1954, 8, 393-411.
57. Stocks, P. Cancer and Goitre. Biometrika 1924, 16, 364-401.
58. Abnet, C.C.; Fan, J.H.; Kamangar, F.; Sun, X.D.; Taylor, P.R.; Ren, J.S.; Mark, S.D.; Zhao, P.; Fraumeni, J.F., Jr.; Qiao, Y.L.; et al. Self-reported goiter is associated with a significantly increased risk of gastric noncardia adenocarcinoma in a large population-based Chinese cohort. Int. J. Cancer 2006, 119, 1508-1510.
59. Golkowski, F.; Szybinski, Z.; Rachtan, J.; Sokolowski, A.; Buziak-Bereza, M.; Trofimiuk, M.; Hubalewska-Dydejczyk, A.; Przybylik-Mazurek, E.; Huszno, B. Iodine prophylaxis-The protective factor against stomach cancer in iodine deficient areas. Eur. J. Nutr. 2007, 46, 251-256.
60. Venturi, S.; Venturi, M. Iodide, thyroid and stomach carcinogenesis: Evolutionary story of a primitive antioxidant? Eur. J. Endocrinol. 1999, 140, 371-372.
61. Amin, H.A.; Kamel, A.M.; Radwan, D.M. The effect of tri-iodothyronine on liver Regeneration after partial hepatectomy in rats: Histological and immunohistochemical study. Egypt J. Histol. 2010, 33, 607-619.
62. Francavilla, A.; Carr, B.I.; Azzarone, A.; Polimeno, L.; Wang, Z.; van Thiel, D.H.; Subbotin, V.; Prelich, J.G.; Starzl, T.E. Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. Hepatology 1994, 20, 1237-1241.
63. Bockhorn, M.; Frilling, A.; Benko, T.; Best, J.; Sheu, S.Y.; Trippler, M.; Schlaak, J.F.; Broelsch, C.E. Tri-iodothyronine as a stimulator of liver regeneration after partial and subtotal hepatectomy. Eur. Surg. Res. 2007, 39, 58-63.
64. Columbano, A.; Simbula, M.; Pibiri, M.; Perra, A.; Deidda, M.; Locker, J.; Pisanu, A.; Uccheddu, A.; Ledda-Columbano, G.M. Triiodothyronine stimulates hepatocyte proliferation in two models of impaired liver regeneration. Cell Prolif. 2008, 41, 521-531.
65. Pibiri, M.; Ledda-Columbano, G.M.; Cossu, C.; Simbula, G.; Menegazzi, M.; Shinozuka, H.; Columbano, A. Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J. 2001, 15, 1006-1013.
66. Alisi, A.; Demori, I.; Spagnuolo, S.; Pierantozzi, E.; Fugassa, E.; Leoni, S. Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis. Cell. Physiol. Biochem. 2005, 15, 69-76.
67. Schwartz, H.L.; Strait, K.A.; Ling, N.C.; Oppenheimer, J.H. Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. J. Biol. Chem. 1992, 267, 11794-11799.
68. Columbano, A.; Pibiri, M.; Deidda, M.; Cossu, C.; Scanlan, T.S.; Chiellini, G.; Muntoni, S.; Ledda-Columbano, G.M. The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas. Endocrinology 2006, 147, 3211-3218.
69. Reddy, A.; Dash, C.; Leerapun, A.; Mettler, T.A.; Stadheim, L.M.; Lazaridis, K.N.; Roberts, R.O.; Roberts, L.R. Hypothyroidism: A possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin. Gastroenterol. Hepatol. 2007, 5, 118-123.
70. Hassan, M.M.; Kaseb, A.; Li, D.; Patt, Y.Z.; Vauthey, J.N.; Thomas, M.B.; Curley, S.A.; Spitz, M.R.; Sherman, S.I.; Abdalla, E.K.; et al. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States. Hepatology 2009, 49, 1563-1570.
71. Ledda-Columbano, G.M.; Perra, A.; Loi, R.; Shinozuka, H.; Columbano, A. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Res. 2000, 60, 603-609.
72. Perra, A.; Kowalik, M.A.; Pibiri, M.; Ledda-Columbano, G.M.; Columbano, A. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology 2009, 49, 1287-1296.
73. Yen, C.C.; Huang, Y.H.; Liao, C.Y.; Liao, C.J.; Cheng, W.L.; Chen, W.J.; Lin, K.H. Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. J. Mol. Endocrinol. 2006, 36, 9-21.
74. Chen, R.N.; Huang, Y.H.; Lin, Y.C.; Yeh, C.T.; Liang, Y.; Chen, S.L.; Lin, K.H. Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology 2008, 149, 3817-3831.
75. Mishkin, S.Y.; Pollack, R.; Yalovsky, M.A.; Morris, H.P.; Mishkin, S. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res. 1981, 41, 3040-3045.
76. Lin, K.H.; Shieh, H.Y.; Chen, S.L.; Hsu, H.C. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol. Carcinog. 1999, 26, 53-61.
77. Lin, K.H.; Zhu, X.G.; Shieh, H.Y.; Hsu, H.C.; Chen, S.T.; McPhie, P.; Cheng, S.Y. Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 1996, 137, 4073-4081.
78. Lin, K.H.; Zhu, X.G.; Hsu, H.C.; Chen, S.L.; Shieh, H.Y.; Chen, S.T.; McPhie, P.; Cheng, S.Y. Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma. Endocrinology 1997, 138, 5308-5315.
79. Chan, I.H.; Privalsky, M.L. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene 2006, 25, 3576-3588.
80. Lin, K.H.; Wu, Y.H.; Chen, S.L. Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators. Endocrinology 2001, 142, 653-662.
81. Chan, I.H.; Privalsky, M.L. Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire. Oncogene 2009, 28, 4162-4174.
82. Barlow, C.; Meister, B.; Lardelli, M.; Lendahl, U.; Vennstrom, B. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J. 1994, 13, 4241-4250.
83. Chen, R.N.; Huang, Y.H.; Yeh, C.T.; Liao, C.H.; Lin, K.H. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res. 2008, 68, 1697-1706.
84. Liao, C.H.; Yeh, C.T.; Huang, Y.H.; Wu, S.M.; Chi, H.C.; Tsai, M.M.; Tsai, C.Y.; Liao, C.J.; Tseng, Y.H.; Lin, Y.H.; et al. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology 2012, 55, 910-920.
85. Lin, K.H.; Lin, Y.W.; Lee, H.F.; Liu, W.L.; Chen, S.T.; Chang, K.S.; Cheng, S.Y. Increased invasive activity of human hepatocellular carcinoma cells is associated with an overexpression of thyroid hormone beta 1 nuclear receptor and low expression of the anti-metastatic nm23 gene. Cancer Lett. 1995, 98, 89-95.
86. Martinez-Iglesias, O.; Garcia-Silva, S.; Tenbaum, S.P.; Regadera, J.; Larcher, F.; Paramio, J.M.; Vennstrom, B.; Aranda, A. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res. 2009, 69, 501-509.
87. Martinez-Iglesias, O.; Garcia-Silva, S.; Regadera, J.; Aranda, A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One 2009, 4, e6428.
88. Gupta, R.; Khosroshahi, A.; Shinagare, S.; Fernandez, C.; Ferrone, C.; Lauwers, G.Y.; Stone, J.H.; Deshpande, V. Does autoimmune pancreatitis increase the risk of pancreatic carcinoma? A retrospective analysis of pancreatic resections. Pancreas 2013, 42, 506-510.
89. Komatsu, K.; Hamano, H.; Ochi, Y.; Takayama, M.; Muraki, T.; Yoshizawa, K.; Sakurai, A.; Ota, M.; Kawa, S. High prevalence of hypothyroidism in patients with autoimmune pancreatitis. Dig. Dis. Sci. 2005, 50, 1052-1057.
90. Fyssas, I.; Syrigos, K.N.; Konstantoulakis, M.M.; Tsibloulis, V.; Manouras, A.; Peveretos, P.; Golematis, B.C. Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncol. 1997, 36, 65-68.
91. Ledda-Columbano, G.M.; Perra, A.; Pibiri, M.; Molotzu, F.; Columbano, A. Induction of pancreatic acinar cell proliferation by thyroid hormone. J. Endocrinol. 2005, 185, 393-399.
92. Hosotani, R.; Kawaguchi, M.; Masui, T.; Koshiba, T.; Ida, J.; Fujimoto, K.; Wada, M.; Doi, R.; Imamura, M. Expression of integrin alphaVbeta3 in pancreatic carcinoma: Relation to MMP-2 activation and lymph node metastasis. Pancreas 2002, 25, e30-e35.
93. Rennert, G.; Rennert, H.S.; Pinchev, M.; Gruber, S.B. A case-control study of levothyroxine and the risk of colorectal cancer. J. Natl. Cancer Inst. 2010, 102, 568-572.
94. Shu, X.; Ji, J.; Li, X.; Sundquist, J.; Sundquist, K.; Hemminki, K. Cancer risk in patients hospitalised for Graves' disease: A population-based cohort study in Sweden. Br. J. Cancer 2010, 102, 1397-1399.
95. Rose, D.P.; Davis, T.E. Plasma thyronine levels in carcinoma of the breast and colon. Arch. Intern. Med. 1981, 141, 1161-1164.
96. Horkko, T.T.; Tuppurainen, K.; George, S.M.; Jernvall, P.; Karttunen, T.J.; Makinen, M.J. Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int. J. Cancer 2006, 118, 1653-1659.
97. Markowitz, S.; Haut, M.; Stellato, T.; Gerbic, C.; Molkentin, K. Expression of the ErbA-beta class of thyroid hormone receptors is selectively lost in human colon carcinoma. J. Clin. Investig. 1989, 84, 1683-1687.
98. Vonlaufen, A.; Wiedle, G.; Borisch, B.; Birrer, S.; Luder, P.; Imhof, B.A. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod. Pathol. 2001, 14, 1126-1132.
99. Jiskra, J.; Limanova, Z.; Barkmanova, J.; Smutek, D.; Friedmannova, Z. Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol. Res. 2004, 53, 693-702.
100. Hellevik, A.I.; Asvold, B.O.; Bjoro, T.; Romundstad, P.R.; Nilsen, T.I.; Vatten, L.J. Thyroid function and cancer risk: A prospective population study. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 570-574.
101. Carriere, R.M. The influence of thyroid and testicular hormones on the epithelium of crypts of Lieberkuhn in the rat's intestine. Anat. Rec. 1966, 156, 423-431.
102. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469-480.
103. Plateroti, M.; Kress, E.; Mori, J.I.; Samarut, J. Thyroid hormone receptor alpha1 directly controls transcription of the beta-catenin gene in intestinal epithelial cells. Mol. Cell. Biol. 2006, 26, 3204-3214.
104. Kress, E.; Rezza, A.; Nadjar, J.; Samarut, J.; Plateroti, M. The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. J. Biol. Chem. 2009, 284, 1234-1241.
105. Kress, E.; Skah, S.; Sirakov, M.; Nadjar, J.; Gadot, N.; Scoazec, J.Y.; Samarut, J.; Plateroti, M. Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis. Gastroenterology 2010, 138, 1863-1874.
106. Iishi, H.; Tatsuta, M.; Baba, M.; Okuda, S.; Taniguchi, H. Enhancement by thyroxine of experimental carcinogenesis induced in rat colon by azoxymethane. Int. J. Cancer 1992, 50, 974-976.
107. Reinmuth, N.; Liu, W.; Ahmad, S.A.; Fan, F.; Stoeltzing, O.; Parikh, A.A.; Bucana, C.D.; Gallick, G.E.; Nickols, M.A.; Westlin, W.F.; et al. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003, 63, 2079-2087.
108. Kester, M.H.; Kuiper, G.G.; Versteeg, R.; Visser, T.J. Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology 2006, 147, 5845-5854.
109. Lee, J.K.; Gordon, P.R.; Stall, G.M.; Gilchrest, B.A.; Kaplan, M.M. Phenolic and tyrosyl ring iodothyronine deiodination by the Caco-2 human colon carcinoma cell line. Metabolism 1989, 38, 1154-1161.
110. Dentice, M.; Luongo, C.; Ambrosio, R.; Sibilio, A.; Casillo, A.; Iaccarino, A.; Troncone, G.; Fenzi, G.; Larsen, P.R.; Salvatore, D. Beta-Catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. Gastroenterology 2012, 143, 1037-1047.
111. Clark, L.C.; Combs, G.F., Jr.; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F.; Gross, E.G.; et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276, 1957-1963.
112. Peters, U.; Chatterjee, N.; Church, T.R.; Mayo, C.; Sturup, S.; Foster, C.B.; Schatzkin, A.; Hayes, R.B. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 315-320.
113. Russo, M.W.; Murray, S.C.; Wurzelmann, J.I.; Woosley, J.T.; Sandler, R.S. Plasma selenium levels and the risk of colorectal adenomas. Nutr. Cancer 1997, 28, 125-129.
114. Kipp, A.; Banning, A.; van Schothorst, E.M.; Meplan, C.; Schomburg, L.; Evelo, C.; Coort, S.; Gaj, S.; Keijer, J.; Hesketh, J.; et al. Four selenoproteins, protein biosynthesis, and Wnt signalling are particularly sensitive to limited selenium intake in mouse colon. Mol. Nutr. Food Res. 2009, 53, 1561-1572.
115. Berkenstam, A.; Kristensen, J.; Mellstrom, K.; Carlsson, B.; Malm, J.; Rehnmark, S.; Garg, N.; Andersson, C.M.; Rudling, M.; Sjoberg, F.; et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. USA 2008, 105, 663-667.
116. Villicev, C.M.; Freitas, F.R.; Aoki, M.S.; Taffarel, C.; Scanlan, T.S.; Moriscot, A.S.; Ribeiro, M.O.; Bianco, A.C.; Gouveia, C.H. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J. Endocrinol. 2007, 193, 21-29.
117. Renehan, A.G.; Tyson, M.; Egger, M.; Heller, R.F.; Zwahlen, M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371, 569-578.
118. Van Beeren, H.C.; Jong, W.M.; Kaptein, E.; Visser, T.J.; Bakker, O.; Wiersinga, W.M. Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: In vitro and in vivo evidence. Endocrinology 2003, 144, 552-558.
119. Hope, K.J.; Jin, L.; Dick, J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5, 738-743.
120. Kucia, M.; Ratajczak, M.Z. Stem cells as a two edged sword-From regeneration to tumor formation. J. Physiol. Pharmacol. 2006, 57, 5-16.
121. Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer. Nature 2005, 434, 843-850.
122. Simmen, F.A.; Mercado, C.P.; Zavacki, A.M.; Huang, S.A.; Greenway, A.D.; Kang, P.; Bowman, M.T.; Prior, R.L. Soy protein diet alters expression of hepatic genes regulating fatty acid and thyroid hormone metabolism in the male rat. J. Nutr. Biochem. 2010, 21, 1106-1113.